TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Wound Protector Dual-ring Alexis® in Pancreaticoduodenectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for elective PD~* Age ≥ 18 years~* Ability of the subject to understand character and individual consequences of the clinical trial~* Written informed consent~Exclusion Criteria:~* Under 18 years of age~* Unable to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alexis® device (Type: EXPERIMENTAL): In this group, we will be used WP dual-ring Alexis® (Figure 1). The Alexis® 's size will be decided on the basis of abdominal incision (Alexis® X-Large or Alexis® XX-Large will be used for 11-17cm or 17-25 cm incision length respectively)
- Standard 3M™ Steri-Drape 2 (Type: ACTIVE_COMPARATOR): In this group, we will be used Standard 3M™ Steri-Drape 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Benefits of Using a Range of Wound Care Products From a Single Manufacturer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
All healthcare professionals of the Billericay team responsible for dressing changes who are willing to take part in this study and give their written informed consent.~Inclusion Criteria for the patients:~* Patients giving their informed consent and with an open wound being treated by the community nursing team~* All patients whose wounds can be treated with BSN medical UK Product range for wound and leg ulcer management.~Exclusion Criteria for the patients:~* Age \<18 years~* Subjects who do not give their consent for any reason~* Subjects who are unable to read and understand patient information sheet and consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prospective Data (Type: EXPERIMENTAL): Use of BSN medical UK range of wound dressings and compression products for 12 weeks treatment period Training and testing of woundcare nursing competencies Quality of Life questionnaire for patients
- Historical data (Type: NO_INTERVENTION): Historical data from the three months prior to the study on time needed for nurse training, number of referrals to the Tissue Viability Team, costs of dressings used, number of patients with wounds treated, types of wounds, number of wound closures and duration of treatment .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lexapro for Major Depression in Patients With Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients will be 20 males or females above the age of 18 with a current major depressive episode, as defined by DSM-IV and assessed on the MINI, of at least 4 weeks duration.~2. All subjects must have epilepsy, defined as the recurrence of seizures that are unprovoked and unpredictable, requiring treatment with an anti-epileptic medication under the care of a neurologist.~3. Subjects must be stabilized on their antiepileptic drug (AED) regimen for the previous 2 months.~4. If a vagus nerve stimulator is in place, the settings must be unchanged for the previous 2 months.~5. Patients must be ages 18 - 75 and have a 24 item Hamilton Depression Rating Scale Score (HAM-D) at intake \>/= 20.~6. Subjects must be fluent in English and have the capacity to understand the nature of the study and sign the written informed consent.~Exclusion Criteria:~1. Axis II diagnosis of antisocial, schizotypal or severe borderline personality disorder(defined as patients who are high risk for being unable to complete the study due to hospitalization, suicide attempts, significant self-mutilation, or other self-injurious or destructive behavior).~2. History of psychosis, mania or hypomania.~3. Subjects with more than 10 seizures per month that involve impairment of consciousness, such as complex partial or generalized seizures.~4. Subjects unable to count seizures accurately, or do not have a someone in their home who can count seizures accurately .~5. Unstable medical or neurological disorder (other than epilepsy).~6. Epilepsies related to a progressive neurologic disease such as a brain tumor.~7. Substance abuse including ETOH within the past 6 months.~8. Need for concurrent psychotropic drugs with the exception of AEDs or zolpidem for sleep.~9. Concurrent or recent (within 3 months) entry into a new psychotherapy.~10. Actively or acutely suicidal.~11. Failure to respond to escitalopram or to two or more other adequate antidepressant trials in the past year.~12. Pregnancy or lactation.~13. Females of child bearing potential who do not practice adequate contraception.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lexapro (Type: EXPERIMENTAL): escitalopram 10 mg or 20 mg/d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Education in Hand and Wrist Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient over the age of 18 years with a closed carpal, metacarpal, or distal radius fracture undergoing outpatient surgical management at Grady Memorial Hospital, who is willing to participate and mentally capable to consent.~Exclusion Criteria:~* Patients who are inpatients at the time of surgery. Patients who have concomitant injuries on the same extremity as the carpal, metacarpal, or distal radius fracture. Patients with open fractures. Patients unable to tolerate non-steroidal anti-inflammatory drugs (NSAIDs). Non-English speaking patients will be excluded.~* Adults who are unable to consent will not be included.~* Individuals who are not yet adults will not be included.~* Pregnant women will not be included.~* Prisoners will not be included.~* Cognitively impaired individuals or individuals with impaired decision-making capacity will not be included.~* Individuals who speak English will be included. Individuals who have limited English proficiency but speak Spanish as a primary language will not be eligible for inclusion. Spanish-speaking patients will be excluded because the components of the educational protocol (video, questionnaires, surveys) are not available in Spanish.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): Patients in the experimental arm will receive standardized preoperative education in the form of a brief video, interactive quiz, and written handout.~All patients will receive standardized multimodal pain management consisting of a long-acting peripheral nerve block, scheduled non-opioid pain medications, an opioid prescription to be taken only as needed, and adjunctive medicines to be taken as needed for any side effects.
- Control Arm (Type: ACTIVE_COMPARATOR): Patients in the control arm will receive education per the provider's preference (current standard of care).~All patients will receive standardized multimodal pain management consisting of a long-acting peripheral nerve block, scheduled non-opioid pain medications, an opioid prescription to be taken only as needed, and adjunctive medicines to be taken as needed for any side effects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsing-Remitting MS~* On disease modifying treatment for 6 months~* No relapse within the previous 30 days~* BMI 25-55 kg/m2~* Self-identify as not currently meeting recommendations for healthy diet and physical activity~* Ambulatory with or without assistance~* Reliable access to the internet via computer or smartphone~* Responsible for their personal food preparation or have input into the food prepared for them~* Score indicating low cognitive functioning on the Telephone Interview for Cognitive Status assessment~Exclusion Criteria:~* Physician does not approve participation~* Use of the following diabetes medications: Acetohexamide, Chlorpropamide (Diabinese), Tolbutamide (Orinase, Tol-Tab), Tolazamide (Tolinase), Glipizide (Glucotrol, Glucotrol XL, Metaglip), Glyburide (Micronase, DiaBeta, Glynase, Glucovance), Glimepiride (Amaryl), Humalog or lispro, Novolog or aspart, Apidra or glulisine, Regular (R) humulin or novolin, Velosulin (for use in the insulin pump), NPH (N), Lente (L), Ultralente (U), Lantus, Levemir or detemir, Humulin 70/30, Novolin 70/30, Novolog 70/30, Humulin 50/50, or Humalog mix 75/25~* Already on a specific diet meant to improve health~* Heart attack, stroke, or heart bypass surgery less than 6 months ago~* Pulmonary disease, cardiovascular disease or renal failure less than 6 months ago~* Smoking~* Cancer, HIV or liver/kidney disease~* Inability to travel to Lakeshore for testing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BIPAMS (Type: ACTIVE_COMPARATOR): All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS group will continue receiving the established BIPAMS intervention for the remainder of the trial.
- BIPAMS + Diet (Type: EXPERIMENTAL): All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS+Diet arm will begin receiving dietary materials in week 9.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Between the age of 5 and 18 years old~* Clinical diagnosis of Stargardt Disease~* Molecular confirmation of Stargardt Disease (with 2 identified mutations in ABCA4)~* Visual acuity better than 20/100~Exclusion Criteria:~* Limited central vision, defined as visual acuity worse than 20/100~* A diagnosis of any other retinal degenerative disease

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Epidemiology of Interstitial Lung Disease

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
No eligibility criteria

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Short-term Cognitive Training in Late-life Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Age \>=55~* Proficiency in English~* Current depressive episode and meet criteria for DSM-IV major depressive disorder~* Hamilton Depression Rating Scale score \>=15~* Able to give informed consent~* Stable medication dosages during the training period~Exclusion Criteria:~* Other DSM-IV Axis I psychiatric disorders, except for anxiety disorders due to high comorbidity with mood disorders~* Mini-Mental State Examination score of \<26~* Diagnosis of dementia~* Neurological and medical conditions known to affect cognition (e.g., stroke, head injury, previous chemotherapy for cancer)~* Unstable medical illnesses requiring active treatment~* Vision or hearing impairment affecting ability to participate in training

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alternative Uses Training (Type: OTHER): In this task, subjects are asked to produce atypical and alternative uses for common daily objects.
- Word Association Training (Type: OTHER): In this task, subjects are asked to generate the first word that comes to their mind, and thus, encourages more general and spontaneous divergent thinking.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. more than 20 years old~2. HCCs diagnosed by AASLD image criteria or pathology~3. Intermediate-stage HCCs that TACE is indicated~4. chronic HBV carrier with detectable HBV DNA in blood~5. ECOG performance status (PST) 0-2~6. Child-Pugh score ≦7~7. serum bilirubin \< 2 mg/dL~8. prothrombin time prolongation \< 3 seconds~9. willingness to adhere to treatment and follow-up plans -~Exclusion Criteria:~1. any vascular invasion by tumors~2. extra-hepatic metastasis~3. concurrent any other malignancy~4. concomitant immunosuppressive therapy~5. HCC recurrence within 2 years of previous curative treatment~6. antiviral therapy for chronic hepatitis B within 6 months before HCC diagnosis~7. concomitant other therapies for HCC except TACE~8. liver cirrhosis with severe gastroesophageal varices (EVF3 or with red color sign), poorly-controlled ascites or hepatic encephalopathy~9. contraindication for invasive procedures such as recent gastrointestinal bleeding or cerebral hemorrhage~10. contraindication to TACE such as allergy to contrast, pregnancy, sepsis, etc.~11. chronic renal failure with eGFR \< 60~12. concurrent any other chronic viral hepatitis with HCV, HDV, or HIV) -

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenofovir treatment (Type: ACTIVE_COMPARATOR): Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
- Placebo (Type: PLACEBO_COMPARATOR): Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Apnea and Fetal Growth Restriction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 50~* Fetal growth restriction (defined as fetal weight \<10th percentile based on at least one routine 2nd trimester ultrasound without a subsequent increase to \>15th percentile on any ultrasounds prior to enrollment)~* Lower limit of gestational age at enrollment 22+0 weeks.~* Upper limit of gestational age at enrollment: adequate time to complete Stages 1 and 2 and if appropriate to be randomized and receive intervention by no later than 32+0 weeks.~* The absence of 2 minor or 1 major markers of aneuploidy.~Exclusion Criteria:~* Other known cause of fetal growth restriction (including congenital anomalies, intrauterine infection, or multiple gestation)~* Reversed end-diastolic flow in the umbilical artery~* Preexisting diagnosis of OSA being treated with aPAP~* Chronic pulmonary disease (cystic fibrosis, moderate persistent asthma)~* Hemoglobinopathies (sickle cell anemia, thalassemia)~* Maternal craniofacial anomalies~* Premature rupture of membranes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- aPAP (Type: EXPERIMENTAL): Nightly use of aPAP when sleeping through the date of delivery
- No aPAP (Type: NO_INTERVENTION): No use of aPAP (standard of care)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 18 years~* Patients affected by CLL / SLL~* Presence of active disease defined as the presence of one of the following:~Disease related symptoms (weight loss \>10% in the last 6 months, fever \>38° C for 2 weeks without evidence of infection, or marked asthenia, or profuse sweating without evidence of infection) Massive nodes (at least 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy Massive (at least 6 cm below left costal margin) or progressive or symptomatic splenomegaly Progressive lymphocytosis (increased \>50% in 2 months) or lymphocyte doubling time \< 6 months Evidence of progressive bone marrow insufficiency seen as evidence of or worsening of anemia and or thrombocytopenia Autoimmune anemia and or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy~Exclusion Criteria:~* Age \< 18 years~* Patients with cardiac, pulmonary, neurological, psychiatric or serious metabolic conditions not related to CLL / SLL~* Altered hepatic function (bilirubin, GOT, GPT, or gammaGT \> 2 times upper limit of normal) not attributable to CLL / SLL~* Altered renal function (creatinine \> 1,5 times upper limit of normal)~* Patients with serious active infections~* Pregnancy and/ or breastfeeding~* Patients with positive serology for HBSAG or HBCAB without evaluation by a hepatologist~* Patients with positive serology for HIV~* Life expectancy of less than 12 months~* Not taking any other experimental drugs~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Cladribine (2CdA).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab cladribine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Protective Effects of Lidocaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* elective colorectal surgery~Exclusion Criteria:~* ASA \> 3~* history of anti-inflammatory therapy~* history of inflammatory bowl diseases~* history of chronic pain treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Lidocaine i.v
- 2 (Type: ACTIVE_COMPARATOR): intraoperatively lidocaine epidural postoperatively lidocaine i.v.
- 3 (Type: ACTIVE_COMPARATOR): intraoperatively lidocaine i.v. postoperatively lidocaine epidural
- 4 (Type: ACTIVE_COMPARATOR): lidocaine epidural
- 5 (Type: PLACEBO_COMPARATOR): placebo i.v.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues